ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Artificial Intelligence In The Diagnosis And Prediction Of Breast Cancer-Related Lymphedema: A Scoping Review.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLymphedema is a chronic complication of breast cancer treatments that can significantly impact the well-being of survivors. This scoping review aims to evaluate the role of artificial intelligence (AI) in enhancing diagnostic precision and supporting timely interventions.
methodsPubMed, Scopus, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from database inception until September 2024. Studies were included if they examined AI-based techniques for detecting lymphedema, assessing severity, and/or facilitating early diagnosis. Inclusion criteria required studies to be published in English with full-text availability. Editorials, review papers, and inaccessible full-text studies were excluded.
resultsFrom 300 studies identified from the database search, 13 studies met the inclusion criteria. The investigated AI-based models used input data such as Electronic Health Record (EHR) and clinical data (5 studies, 38.5%), patient-reported symptoms and demographics (4 studies, 30.8%), imaging (3 studies, 23.1%), and clinical factors like BMI and hypertension (2 studies, 15.4%) for outcome prediction. The most commonly used AI model was built using the Support Vector Machine (SVM) algorithm, which appeared in 8 studies (61.5%) and was often combined with other supervised learning techniques. Risk prediction models achieved accuracy rates of 81% to 93.75%, with sensitivity of 95.65%, specificity of 91.03%, and Area Under the Curve (AUC) of 0.751. Models classifying lymphedema severity demonstrated accuracy rates between 81 and 91%, with the best-performing models achieving a balanced accuracy of 99.4% and AUC ranging from 0.889 to 0.931.
conclusionsAI demonstrates potential in improving the diagnosis and prediction of breast cancer-related lymphedema, offering enhanced diagnostic capabilities and personalized interventions. Further research is required to address data standardization, model validations, and the development of frameworks for clinical implementation.
Indexed as
Identifiers
42008025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.